Skip to Content
200 Hawkins Drive
358 Medical Research Facility
Iowa City, Iowa 52242-2600
Phone: (319) 356-4848
This pilot study is a controlled, randomized study to determine the safety and effectiveness of laser therapy for the eradication of microorganisms in an endotracheal tube. Sixty subjects will be studied at two sites. All 60 subjects will be enrolled and randomized into one of two groups, 30 subjects (treatment group) will receive PDT (laser therapy) plus standard-of care and 30 subjects (control group) will receive only the standard-of-care for intubated subjects. Subjects must have been recently intubated orally with endotracheal tube (within 36 hours) and placed on a mechanical ventilator.
The purpose of this study is to evaluate the safety of how the body metabolizes a medication called oxfendazole. The medication is being tested to see if it can be used to treat humans with neurocysticercosis, which is a disease caused by a parasite that can enter the brain and cause seizures and other problems. Approximately 50,000 people worldwide die each year because of this parasite, and it is estimated that 1000 cases occur annually in the United State. The current treatment requires multiple doses of medication over the course of several weeks and a complete cure is only successful in 50% of the cases. Studies in pigs show that oxfendazole is able to kill this parasite with a single dose of medication. These data suggest that oxfendazole has the potential to be useful since a single oral dose might be a way to treat neurocysticercosis in humans.
We are currently recruiting volunteers who are 18 to 45 years of age and are in good health. If you are a woman who is able to have children, you will not be able to participate.
This study will be the first test of oxfendazole in humans. Subjects will be given a single dose of the drug and we will test blood and urine to see how much of the drug gets into the blood stream and how long it lasts in the body. We will also follow subjects to see how they tolerate the medication. Some people in this study will get a placebo and some people will get oxfendazole.
To learn more, call 319-356-4848 or e-mail firstname.lastname@example.org.
Adults age 65 years and older who are in good health are invited to participate in an H7N9 flu vaccine study at the University of Iowa.
The study will compare the safety and effectiveness of an H7N9 vaccine at different dosages and different time intervals. The vaccine includes an adjuvant called MF59.
The study involves 5-6 clinic visits and 8-9 phone calls over a period of 18 months.
Enrollment will occur in the next 4-6 weeks.
Compensation is available.To learn more call 319-356-4848 or email email@example.com.
Interested in hearing about our latest studies? Sign up to be a part of our registry. As a member of our registry, we will notify you of any studies we are doing that you may be eligible to participate in.
Simply complete this online registration form to become a member.
Copyright © 2015 The University of Iowa. All Rights Reserved.